Immunobiology of Diabetes and Tuberculosis
Stopped early · Not applicable
Conditions studied: Tuberculosis, Diabetes Mellitus
In brief
The study hypothesis is that type 2 diabetics have abnormal cell-mediated immunity to tuberculosis manifesting as altered cytokine responses by peripheral blood mononuclear cells (PBMCs). This hypothesis will be tested using the live tuberculosis vaccine, Bacille Calmette-Guerin (BCG), in U.S.-born type 2 diabetics and nondiabetics. The investigators will control for potential confounding by age, sex, race, comorbidities, and select medications. Expression of key cytokines will be measured with real-time polymerase chain reaction.
Key facts
- Study ID
- NCT00568854
- Run by
- Stanford University
- People needed
- 10
- Starts
- 2007-04-01
- Expected to finish
- 2008-03-01
- Last updated by the study team
- 2016-08-16
Who can join
Age: 30 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.